SELECTIVE EATING AND GUT MICROBIOTA IN AUTISM SPECTRUM DISORDER: A CLINICAL AND PHARMACEUTICAL APPROACH

Abstract

Autism Spectrum Disorder (ASD) is a neurodevelopmental condition characterized by impairments in communication, social interaction, and behavior, often associated with nutritional and gastrointestinal disorders. In this context, alterations in the intestinal microbiota and feeding difficulties may contribute to nutritional deficiencies and negatively affect the quality of life of individuals with ASD. This study aimed to analyze the role of pharmaceutical care in nutritional intervention and in the modulation of intestinal microbiota in patients with ASD. This study consists of a qualitative literature review, carried out through searches in scientific databases, considering publications between 2020 and 2025 related to the topic. The results showed that individuals with ASD present a high prevalence of food selectivity, which may lead to nutritional deficiencies and compromise neurological development and overall health. In addition, changes in the intestinal microbiota were found to be associated with the worsening of gastrointestinal and behavioral symptoms. In this context, nutritional interventions and appropriate supplementation may contribute to the clinical management of the disorder. Furthermore, the pharmacist plays an important role in guiding, dispensing, and monitoring the use of nutritional supplements, promoting their rational and safe use. It is concluded that pharmaceutical care is essential within the multidisciplinary team, contributing to improvements in nutritional status, quality of life, and comprehensive care for patients with ASD.